Beam Therapeutics Stock Market Value
| BEAM Stock | USD 23.58 0.91 3.72% |
| Symbol | Beam |
Beam Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Beam Therapeutics. If investors know Beam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Beam Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.58) | Revenue Per Share 4.273 | Quarterly Revenue Growth (0.17) | Return On Assets (0.09) | Return On Equity (0.18) |
The market value of Beam Therapeutics is measured differently than its book value, which is the value of Beam that is recorded on the company's balance sheet. Investors also form their own opinion of Beam Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Beam Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Beam Therapeutics' market value can be influenced by many factors that don't directly affect Beam Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Beam Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Beam Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Beam Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Beam Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Beam Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Beam Therapeutics.
| 12/03/2022 |
| 11/22/2024 |
If you would invest 0.00 in Beam Therapeutics on December 3, 2022 and sell it all today you would earn a total of 0.00 from holding Beam Therapeutics or generate 0.0% return on investment in Beam Therapeutics over 720 days. Beam Therapeutics is related to or competes with Editas Medicine, Crispr Therapeutics, Caribou Biosciences, Verve Therapeutics, Intellia Therapeutics, Fate Therapeutics, and Prime Medicine,. Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from seriou... More
Beam Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Beam Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Beam Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.66 | |||
| Information Ratio | (0) | |||
| Maximum Drawdown | 20.75 | |||
| Value At Risk | (7.94) | |||
| Potential Upside | 7.79 |
Beam Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Beam Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Beam Therapeutics' standard deviation. In reality, there are many statistical measures that can use Beam Therapeutics historical prices to predict the future Beam Therapeutics' volatility.| Risk Adjusted Performance | 0.0233 | |||
| Jensen Alpha | (0.22) | |||
| Total Risk Alpha | (0.41) | |||
| Sortino Ratio | (0) | |||
| Treynor Ratio | 0.0217 |
Beam Therapeutics Backtested Returns
Beam Therapeutics secures Sharpe Ratio (or Efficiency) of -0.0334, which signifies that the company had a -0.0334% return per unit of standard deviation over the last 3 months. Beam Therapeutics exposes twenty-nine different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Beam Therapeutics' risk adjusted performance of 0.0233, and Mean Deviation of 3.08 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 3.43, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Beam Therapeutics will likely underperform. At this point, Beam Therapeutics has a negative expected return of -0.14%. Please make sure to confirm Beam Therapeutics' sortino ratio, semi variance, and the relationship between the standard deviation and value at risk , to decide if Beam Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.26 |
Poor predictability
Beam Therapeutics has poor predictability. Overlapping area represents the amount of predictability between Beam Therapeutics time series from 3rd of December 2022 to 28th of November 2023 and 28th of November 2023 to 22nd of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Beam Therapeutics price movement. The serial correlation of 0.26 indicates that nearly 26.0% of current Beam Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.26 | |
| Spearman Rank Test | 0.4 | |
| Residual Average | 0.0 | |
| Price Variance | 18.0 |
Beam Therapeutics lagged returns against current returns
Autocorrelation, which is Beam Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Beam Therapeutics' stock expected returns. We can calculate the autocorrelation of Beam Therapeutics returns to help us make a trade decision. For example, suppose you find that Beam Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Beam Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Beam Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Beam Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Beam Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Beam Therapeutics Lagged Returns
When evaluating Beam Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Beam Therapeutics stock have on its future price. Beam Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Beam Therapeutics autocorrelation shows the relationship between Beam Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Beam Therapeutics.
Regressed Prices |
| Timeline |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Beam Therapeutics Correlation, Beam Therapeutics Volatility and Beam Therapeutics Alpha and Beta module to complement your research on Beam Therapeutics. To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Beam Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.